Moderna (MRNA)
NASDAQ:MRNA
Want to see MRNA full AI Analyst Report?
MRNA Stock Chart & Stats
$53.72
-$4.21(-8.86%)
At close: 4:00 PM EST
$53.72
-$4.21(-8.86%)
Day’s Range― - ―
52-Week Range$22.28 - $59.55
Previous CloseN/A
Volume7.58M
Average Volume (3M)6.99M
Market Cap
$18.11B
Enterprise Value$18.11B
Total Cash (Recent Filing)$5.21B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Jul 30, 2026EPS Estimate
-2.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.15
Shares Outstanding396,786,250
10 Day Avg. Volume4,909,283
30 Day Avg. Volume6,992,324
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue8.14
Enterprise Value/Gross Profit-58.62
Enterprise Value/Ebitda-6.13
Forecast
1Y Price Target
$44.61Price Target Upside-16.96% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)-8.66
Revenue Forecast (FY)$2.09B
Bulls Say, Bears Say
Bulls Say
MRNA Platform And Approved ProductsRegulatory approvals and an expanding approved infectious-disease portfolio demonstrate durable platform credibility and commercial optionality. The flu+COVID combo approval broadens addressable markets (seasonal/combination vaccines) and supports recurring demand and partnerships over multiple seasons.
Strong Balance Sheet And Low LeverageModerna's sizable equity base and low leverage provide a durable financial buffer to fund multi-year R&D, absorb one-time legal payments, and support manufacturing scale-up. This enhances strategic flexibility and reduces near-term refinancing pressure versus peers with higher leverage.
Clinical Partnerships & Pipeline ProgressRobust long-term efficacy data in collaboration with Merck materially de-risks an oncology mRNA program and strengthens commercial prospects. Positive durable clinical outcomes plus an established partner accelerate regulatory and commercialization potential beyond vaccine revenue dependence.
Bears Say
Sustained Negative Cash FlowPersistent negative OCF and FCF signal structural cash burn that will pressure resources over the next 2–6 months absent sustained revenue gains or deeper cost cuts. Ongoing burn narrows strategic options and increases reliance on existing cash balances and potential external financing.
Large Litigation Settlement & Contingent ExposureA material, near-term cash payment plus up-to-$1.3B contingent liability structurally raises cost of sales and reduces available capital for R&D and commercialization. The contingent nature and appellate timeline create prolonged legal and cash uncertainty affecting multi-year planning.
Profitability & Margin ErosionNegative gross margins and deep operating losses indicate a cost structure misaligned with today's revenue base. Without structural margin recovery from higher product volumes, pricing, or further cost reduction, returns will remain impaired and equity will continue to erode.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $59.55 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $18.11B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Jul 30, 2026 which is in 56 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on May 01, 2026. The company reported -$3.4 earnings per share for the quarter, beating the consensus estimate of -$4.446 by $1.046.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.06.
How many shares outstanding does Moderna have?
Moderna has 396,786,250 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$3.4 in its last earnings report, beating expectations of -$4.446. Following the earnings report the stock price went down -1.241%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$44.61 (-16.96% Downside)
$44.61 (-16.96% Downside)
Blogger Sentiment
Bullish
MRNA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 178.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $433.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.72%
12-Months-Change
Fundamentals
Return on Equity
-36.73%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly constructive commercial and scientific update: strong Q1 revenue growth (driven by international strategic partnerships), multiple regulatory approvals (including the first flu+COVID combo), meaningful cost reductions (adjusted cash cost down 26% YoY) and continued pipeline advancement across respiratory, oncology and rare diseases. Offsetting these positives were a large, near-term litigation settlement charge recognized in Q1 that materially increased cost of sales and GAAP loss, potential contingent legal exposure (up to $1.3B) with multi‑year timing uncertainty, and expected cash drawdown through 2026. On balance, the company demonstrated operational execution and long‑term value drivers while managing a significant one‑time legal headwind.View all MRNA earnings summariesMRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$44.61
▼(-16.96% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Ownership Overview
7.73% Insiders
27.67% Mutual Funds
20.59% Other Institutional Investors
21.48% Public Companies and Individual Investors